GLP-1 receptor agonists not linked to overall gynecologic cancer risk, but cut ovarian cancer risk by 32%
Background
The widespread use of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for managing Type 2 Diabetes Mellitus (T2DM) and obesity has raised questions about their long-term effects on cancer risk. Given the established links between metabolic dysfunction and the development of various gynecologic malignancies, understanding the potential association between GLP-1RA use and these cancers is clinically crucial. Current evidence regarding this specific link has been inconsistent, leaving a significant gap in defining the comprehensive safety profile of these increasingly popular medications.
Study Design
Researchers conducted a systematic meta-analysis, searching PubMed (from 1966) and Embase (from 1974) through February 15, 2026. The search focused on observational cohort studies evaluating the association between GLP-1RA use and gynecologic cancer outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) from the identified studies were pooled using random-effects models. The final analysis included nine retrospective cohort studies to assess the overall and subtype-specific risks.
Results
The meta-analysis of nine retrospective cohort studies found that GLP-1RA use was not significantly associated with overall gynecologic cancer risk (HR 0.80; 95% CI: 0.63, 1.01). However, subtype analyses revealed a statistically significant reduction in risk for ovarian cancer. Associations for endometrial, cervical, and other gynecologic cancers were not statistically significant. The authors noted substantial heterogeneity among the included studies. Potential reductions were also observed in obesity populations. These findings, due to their observational nature and heterogeneity, are considered hypothesis-generating.
GLP-1RA use significantly reduced ovarian cancer risk by 32% (HR 0.68; 95% CI: 0.49, 0.93).
Key Findings
- GLP-1RA use was not significantly associated with overall gynecologic cancer risk (HR 0.80; 95% CI: 0.63, 1.01).
- GLP-1RA use reduced ovarian cancer risk by 32% (HR 0.68; 95% CI: 0.49, 0.93).
- No statistically significant associations were found for endometrial or cervical cancers.
- Potential risk reductions were also observed in obesity populations.
- Substantial heterogeneity was noted among the nine included retrospective cohort studies.
Why It Matters
This meta-analysis offers reassuring evidence for the safety profile of GLP-1RA use concerning overall gynecologic cancer risk, which is a significant practical takeaway for clinicians and patients. While the overall risk was not significantly altered, the observed 32% reduction in ovarian cancer risk is a notable finding that could influence future research and potentially inform prescribing decisions, particularly for individuals at higher risk for ovarian cancer. This suggests that beyond their metabolic benefits, GLP-1RAs might offer a protective effect against specific cancer types, warranting further investigation into underlying mechanisms and potential clinical applications in cancer prevention strategies. GLP-1RA users can be reassured regarding overall gynecologic cancer risk, with a potential benefit for ovarian cancer.
glp-1ra
gynecologic-cancer
ovarian-cancer
meta-analysis
type-2-diabetes
obesity